Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Input: Consider Input: But following a nationwide lockdown to curb the spread of the coronavirus, the 42-year-old vendor has turned to making plastic face shields for frontline medical workers instead. “I was once a patient myself and I feel like my family owes doctors a lot”, said Linh, who received hospital treatment a few years ago for a blood-related illness. “I want to make these shields to keep them healthy. If they are healthy, then they can protect us”. Last week, Vietnam began a 15-day social distancing campaign to slow the spread of the virus that has seen most non-essential businesses shut, including Linh’s stall. There have been 241 reported cases of the coronavirus in Vietnam and no reported deaths, according to the health ministry. Aggressive contact tracing and a mass quarantine programme have helped keep that tally low. When the lockdown began, Linh assembled a group of family members, friends and fellow vendors to start making the face shields. They can be worn in addition to face masks to better protect medical workers from the tiny virus-carrying droplets released by infected patients. In just a few days, Linh and her gang of volunteers made almost 1,000 face shields, she said, and distributed them to at least three nearby hospitals. Linh said she had drawn on her experience as a hat vendor to line the shields with comfortable padding. She watched media reports of doctors in the United States and consulted a friend who works as a nurse there to perfect the design, she said. The finishing touch? A sticker, with an important message to Vietnam’s medical workers: “Fight Covid-19 disease”. “Keep believing, because we are always with you”. (This story is refiled to correct dateline)

Output: Vietnamese hat seller turns to homemade face shields in virus fight.


Input: Consider Input: Some 1.8 million people in Mozambique need urgent help after Cyclone Idai, the United Nations said in an emergency appeal for $282 million for the next three months. The death toll in Mozambique from the cyclone has risen to 468, according to Mozambican authorities cited by the Portuguese news agency Lusa. There are also 259 dead in Zimbabwe and at least 56 dead in Malawi. Cyclone Idai was “one of the worst weather-related catastrophes in the history of Africa,” U.N. Secretary-General Antonio Guterres told reporters in New York. He raised the specter of hunger, saying the storm inundated Mozambique’s breadbasket on the eve of harvest. The death toll remained at least 761 in Mozambique, Zimbabwe and Malawi, and authorities have warned it is “very preliminary.” More bodies will be found as floodwaters drain away. Emergency responders raced to contain deadly diseases such as cholera, which authorities have said will break out as more than a quarter-million displaced people shelter in camps with little or no clear water and sanitation. Many wells were contaminated by the floods. People are living in tent camps, schools, churches, roads and other impromptu places on higher ground. Many have little but their clothes, squatting over cooking fires and picking their way around stretches of increasingly dirty water or simply walking through it, resigned. The World Health Organization said it is expecting a “spike” in malaria cases in Mozambique. The disease-carrying mosquitoes breed in standing water. WHO also said 900,000 oral cholera vaccines were expected to arrive later this week. Cholera is caused by eating contaminated food or drinking water and can kill within hours. Cases of diarrhea have been reported. “We must not let these people suffer a second disaster through a serious disease outbreak or inability to access essential health services. They have suffered enough,” Dr. Djamila Cabral, the WHO Representative in Mozambique, told reporters in Geneva. She said people in camps were living in “horrific conditions” and that about 55 health centers had been severely damaged. Residents of the camps expressed growing concern. “Surely when people are in a crowded place they are all vulnerable, they face difficulties such as urination and defecation,” Jose Pedro told The Associated Press in Beira. “So the spreading of diseases such as cholera is easy.” There were similar concerns in southern Malawi. In the Bangula camp in Nsanje district, about 5,000 people have just a few toilets. The toilets “are very shallow and some are already full because the area is still waterlogged,” said Joseph Moyo with the Oxfam aid group. Humanitarian assistance continued to arrive, including much-needed air support. The World Food Program received $280,000 from the European Union to support the deployment of a U.N. Humanitarian Air Service helicopter that will deliver assistance to the two worst-hit districts in Zimbabwe, Chimanimani and Chipinge. The United States said it had donated nearly $3.4 million in emergency food assistance to the World Food Program, whose director was touring Beira on Tuesday. A field hospital was being set up in Beira and another is arriving later this week, the International Federation of Red Cross and Red Crescent Societies said. A sanitation system to serve some 22,000 people has arrived and a water purification unit to serve some 25,000 people is expected to arrive on Wednesday, the organization said. “Honestly I am distressed there is still a lot of work to be done in terms of providing the assistance proportional” to the number of people, former Mozambican first lady Graca Machel said in Beira. Bit by bit, the scale of the destruction became clearer. The cyclone reportedly destroyed all houses in the village of Metuchira, home to nearly 38,000 people, the U.N. humanitarian agency said. Amid the relief efforts, grieving people in Mozambique struggled to bury the dead. “Efforts are underway to improve management of dead bodies, as mortuary facilities were either destroyed and/or lack enough facilities and capacity,” the U.N. humanitarian agency said. ___ Associated Press writers Jamey Keaten in Geneva and Cara Anna in Johannesburg contributed. ___ Follow Africa news at https://twitter.com/AP_Africa

Output: ‘Second disaster’ warned in Mozambique as cholera a concern.


Input: Consider Input: “It’s time to go back on offense,” Lechleiter said in a recent interview. New treatments for diabetes and cancer now awaiting approval and increased sales of animal-health products and drugs in China and Japan are some of the aggressive moves he has in mind. He is also counting on a robust success rate among three dozen other experimental drugs now in mid- and late-stage trials, including a cancer drug called ramucirumab. “We’re on the cusp of launching products in cancer and diabetes, two therapeutic areas where we’re well established and where we have built out the infrastructure we need,” Lechleiter said. “And we believe that’s going to be the beginning of our return to growth.”  Skeptical investors only now appear to be catching on to Lilly’s potential upside. After rising only 3 percent in 2013, badly underperforming a 27 percent average advance for other large drugmakers, the stock is up 6 percent this month. “Instead of having to play defense and manage through this difficult patent cliff, the company will be able to use additional cash flow to invest in its pipeline, to partner with others or make bolt-on acquisitions,” said Atlantic Equities analyst Richard Purkiss. “The outlook is much brighter, and they’ll try to get that message across in coming months.”  Lilly, which reports quarterly and 2013 results on Thursday, has forecast earnings of $2.77 to $2.85 per share this year, the final and worst year of its patent cliff. That’s 41 percent less than 2010. Lilly last year sought U.S. approvals for four drugs, three of which Lechleiter said could be approved in 2014: ramucirumab for stomach cancer, and dulaglutide and empagliflozin for type 2 diabetes - the most common form of diabetes, which is closely linked to obesity. Analysts have forecast annual sales of more than $650 million for ramucirumab, saying sales could be far higher if the drug also wins approval for cancers of the colon, lung or liver. But they caution that the diabetes drugs may have a hard time competing against existing options. Lechleiter said Lilly plans to seek approval of necitumumab for squamous-cell lung cancer this year. The medicine, like ramucirumab, was acquired by Lilly through its $6.5 billion purchase of ImClone Systems in 2008. If approved, necitumumab could capture eventual annual sales of more than $1 billion, analysts say. Such sales could make a big difference for Lilly, whose annual revenue of $20 billion is far lower than Big Pharma rivals like Pfizer Inc and Merck & Co. In the meantime, Lilly is testing nearly 40 medicines in mid- and late stage studies, compared with only 7 in those stages of development a decade ago. They include new treatments for cholesterol, psoriasis, lupus, rheumatoid arthritis and Alzheimer’s disease. Animal health unit Elanco, with annual sales of about $2 billion, is thriving as Lilly introduces new products and has expanded the business in China and other fast-growing markets. Many analysts are wary, however, of the company’s ability to win approvals of prescription drugs because it has not launched any major products in recent years and has suffered setbacks in clinical trials, including ramucirumab’s failure to delay progression of breast cancer. Of 20 analysts tracked by Thomson Reuters, 12 have hold or sell ratings on Lilly, versus 8 with buy ratings. Lilly shares trade at 19 times expected 2014 per-share earnings, compared to a price-to-earnings ratio of 14.6 for other large drugmakers. That could be more a reflection of the company’s poor earnings this year than excitement about the stock. “We believe that overall the pipeline will disappoint investors,” said Alex Arfaei of BMO Capital Markets in a research note, citing low sales expectations for ramucirumab and the new diabetes drugs. When Lilly’s Zyprexa was confronted with cheaper generic treatments for schizophrenia in October 2011, it faced one of the industry’s steepest patent cliffs ever, quickly losing 80 percent of its onetime $5 billion in annual sales. Similarly precipitous declines are expected for Cymbalta, Lilly’s $5 billion-a-year antidepressant, which lost U.S. patent protection last month, and for blockbuster osteoporosis treatment Evista, which goes generic in March. Many other large drugmakers, when faced with patent expirations and earnings declines of lesser scope, have resorted to megamergers to cushion the blow from generics and prop up earnings with cost savings. Huge layoffs, sapped morale and poor track records in introducing new drugs are more common results. Pfizer Inc stands out, having snapped up U.S. rivals Warner-Lambert, Pharmacia and Wyeth since 2000. Lechleiter, who began his career at Lilly in 1979 as a senior organic chemist, has steadfastly spurned any suggestion of a big merger: “It’s never entered our minds, and we remain adamantly opposed.”  John Boris, an analyst for Suntrust Robinson Humphrey, said he expects Lilly earnings to grow an average of 10 percent a year between 2015 and 2020, which would make it second to Bristol-Myers Squibb Co in profit growth over that period. Atlantic Equities’ Purkiss said he anticipates Lilly will deliver industry-topping earnings growth in the “mid-teens” percentage range in 2015, 2016 and 2017. “The sentiment has been very negative on Lilly, but it looks like it will go from one of the most growth-starved to the fastest growing of the major U.S. drugmakers and the European players,” Purkiss said. By avoiding a disruptive megamerger, Lilly has allowed itself to press ahead with ambitious research, said Barclays analyst Tony Butler. He said to date the company has met long-term sales and earnings forecasts it provided in 2009 - before patents went over the cliff - while maintaining its generous dividend, with a current yield of 3.6 percent. “At the time, the market was incredibly skeptical about Lilly’s ability to fund its dividend and to have enough remaining cash flow to fund its business,” said Butler. “Lilly proved everybody wrong.”  (This story has been refiled to change second subhead)


Output: Lilly CEO: 'It's time to go back on offense'.